These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 10908954)

  • 1. [Drugs for 'neglected diseases': a bitter pill].
    Veeken H; Pécoul B
    Ned Tijdschr Geneeskd; 2000 Jun; 144(26):1253-6. PubMed ID: 10908954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initiative launched to develop drugs for neglected diseases.
    Frankish H
    Lancet; 2003 Jul; 362(9378):135. PubMed ID: 12870480
    [No Abstract]   [Full Text] [Related]  

  • 3. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
    Liu BC; He L; He G; He Y
    J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Orphan drugs: some legal, ethical and economics aspects].
    Pabst JY
    Rev Epidemiol Sante Publique; 2001 Sep; 49(4):387-96. PubMed ID: 11567205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. US incentive scheme for neglected diseases: a good idea gone wrong?
    Doshi P
    BMJ; 2014 Jul; 349():g4665. PubMed ID: 25099712
    [No Abstract]   [Full Text] [Related]  

  • 6. Developments in the treatment of visceral leishmaniasis.
    den Boer ML; Alvar J; Davidson RN; Ritmeijer K; Balasegaram M
    Expert Opin Emerg Drugs; 2009 Sep; 14(3):395-410. PubMed ID: 19708817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment options for visceral leishmaniasis.
    den Boer M; Davidson RN
    Expert Rev Anti Infect Ther; 2006 Apr; 4(2):187-97. PubMed ID: 16597201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The economics of pediatric formulation development for off-patent drugs.
    Milne CP; Bruss JB
    Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Developing drugs for developing countries.
    Ridley DB; Grabowski HG; Moe JL
    Health Aff (Millwood); 2006; 25(2):313-24. PubMed ID: 16522573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Access for all to quality drugs].
    Videau JY
    Med Trop (Mars); 2002; 62(4):396-400. PubMed ID: 12534178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prescription drug pricing: do competitive forces operate in the pharmaceutical marketplace?
    Margolis RE
    Healthspan; 1994 Feb; 11(2):9-16. PubMed ID: 10132991
    [No Abstract]   [Full Text] [Related]  

  • 12. Orphan drug legislation: lessons for neglected tropical diseases.
    Villa S; Compagni A; Reich MR
    Int J Health Plann Manage; 2009; 24(1):27-42. PubMed ID: 18435430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Orphan drugs--medications for patients with rare diseases].
    Thielke D; Thyssen JP; Hansen BJ
    Ugeskr Laeger; 2006 Jun; 168(23):2236-8. PubMed ID: 16768975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Jumpstarting research into neglected diseases.
    Leslie M
    Cell; 2006 Nov; 127(3):443-5. PubMed ID: 17081963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
    't Hoen E
    Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298
    [No Abstract]   [Full Text] [Related]  

  • 16. [Human African trypanosomiasis: present and future treatment ].
    Dumas M; Bouteille B
    Bull Soc Pathol Exot; 2002 Dec; 95(5):341-4. PubMed ID: 12696372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations.
    Vegter S; Rozenbaum MH; Postema R; Tolley K; Postma MJ
    Clin Ther; 2010 Aug; 32(9):1651-61. PubMed ID: 20974323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of visceral leishmaniasis in 2004.
    Murray HW
    Am J Trop Med Hyg; 2004 Dec; 71(6):787-94. PubMed ID: 15642973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The information revolution reaches pharmaceuticals: balancing innovation incentives, cost, and access in the post-genomics era.
    Rai AK
    Univ Ill Law Rev; 2001; 2001(1):173-210. PubMed ID: 16493845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.